Abstract:

BACKGROUND: Coronary drug-eluting stent implantation can significantly reduce restenosis after coronary intervention and major cardiovascular adverse events, improve patient’s quality of life, is widely used in clinical practice. However, a number of recent meta-analysis shows that compared with bare metal stents, drug-eluting stent significantly increased late stent thrombosis and all-cause death rate.
OBJECTIVE: To observe changes in platelet membrane glycoprotein before and after coronary artery stenting, as well as in follow-up 6 months, to compare the difference of short-term versus medium-term implanted drug-eluting stents or bare metal stents on the platelet activation.
METHODS: A total of 104 patients who were successfully treated with coronary stenting due to acute coronary syndrome between June 2007 and June 2009 were analyzed retrospectively, including 68 cases by use of drug-eluting stents, and 36 cases by use of bare metal stents. Meanwhile 34 patients with suspected acute coronary syndrome were included for the angiography, the patients confirmed as completely normal blood vessels served as the control group. The CD62p, CD63 and thrombin-sensitive protein expression rate in peripheral blood of patients was compared.
RESULTS AND CONCLUSION: Given the same anti-platelet therapy for 6 months, compared with bare metal stents, the influence of drug-eluting stent implantation on platelet activation was still evident, which may be associated with the increase of late stent thrombosis of drug-eluting stent. Further study should verify whether standard 12-month anticoagulant treatment, which is currently advocated, is adequate, and investigate clinical significance of the detection of platelet activation on antiplatelet therapy after stenting.